Results 21 to 30 of about 774,384 (405)

Immunomodulatory treatment of interstitial lung disease

Therapeutic Advances in Respiratory Disease, 2022
Interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) have an array of immunomodulatory treatment options compared with IPF, due to their inflammatory component.
L. van den Bosch, F. Luppi, G. Ferrara, M. Mura   +3 more
semanticscholar   +1 more source

Interstitial lung disease in Primary Sjögren's syndrome

BMC Pulmonary Medicine, 2022
Background Interstitial lung disease (ILD) may cause life-threatening complications of primary Sjogren’s syndrome (pSS), and has a poor prognosis in terms of survival and quality of life.
wei lin, Zhifei Xin, Jianlong Zhang, Ning Liu, X. Ren, Meilu Liu, Ya-latu Su, Yixuan Liu, Liu Yang, Shaoying Guo, Yupeng Yang, Yang Li, Jingjing Cao, Xiaoran Ning, Jingjing Li, He Xue, N. Niu, Ying-qun Chen, Fang Li, Lijun Sun, Xiaopeng Zhang, Fengxiao Zhang, Wen Zhang   +22 more
semanticscholar   +1 more source

The Genetics of Interstitial Lung Diseases [PDF]

European Respiratory Review, 2019
Interstitial lung diseases (ILDs) are a set of heterogeneous lung diseases characterised by inflammation and, in some cases, fibrosis. These lung conditions lead to dyspnoea, cough, abnormalities in gas exchange, restrictive physiology (characterised by decreased lung volumes), hypoxaemia and, if progressive, respiratory failure.
Raphael Borie, Pierre Le Guen, Mada Ghanem, Camille Taillé, Clairelyne Dupin, Philippe Dieudé, Caroline Kannengiesser, Bruno Crestani   +7 more
openaire   +3 more sources

Interstitial Lung Disease in the Elderly [PDF]

Chest, 2017
Despite the relationship between idiopathic pulmonary fibrosis (IPF) and advancing age, little is known about the epidemiology of interstitial lung disease (ILD) in the elderly. We describe the diagnoses, clinical characteristics, and outcomes of patients who were elderly at the time of ILD diagnosis.Among subjects from a prospective cohort study of ...
Patterson, Karen C, Shah, Rupal J, Porteous, Mary K, Christie, Jason D, D’Errico, Carly A, Chadwick, Matthew, Triano, Matthew J, Deshpande, Charuhas, Rossman, Milton D, Litzky, Leslie A, Kreider, Maryl, Miller Jr, Wallace T   +11 more
openaire   +2 more sources

Clinicoserological features of antisynthetase syndrome (ASyS)-associated interstitial lung disease presenting to respiratory services: comparison with idiopathic pulmonary fibrosis and ASyS diagnosed in rheumatology services

BMJ Open Respiratory Research, 2021
Introduction Antisynthetase syndrome (ASyS) is a rare autoimmune connective tissue disease (CTD), associated with autoantibodies targeting tRNA synthetase enzymes, that can present to respiratory (interstitial lung disease (ILD)) or rheumatology ...
Harsha Gunawardena, Huzaifa I Adamali, Havra H Adamali, Caroline Cotton, Ben Mulhearn, Hina Iftikhar, John David Pauling, Lisa Spencer   +7 more
doaj   +1 more source

Variability in Global Prevalence of Interstitial Lung Disease

Frontiers in Medicine, 2021
There are limited epidemiologic studies describing the global burden and geographic heterogeneity of interstitial lung disease (ILD) subtypes. We found that among seventeen methodologically heterogenous studies that examined the incidence, prevalence and
B. Kaul, V. Cottin, H. Collard, C. Valenzuela   +3 more
semanticscholar   +1 more source

Palliative care for people with non-malignant lung disease: summary of current evidence and future direction [PDF]

, 2013
Background: The physical and psychosocial needs of patients with chronic non-malignant lung disease are comparable to those with lung cancer. This article will focus on chronic obstructive pulmonary disease, interstitial lung disease and cystic fibrosis ...
Boland, Jason, Martin, Jonathan, Ross, Joy R, Ross, Joy R., Wells, Athol U, Wells, Athol U.   +5 more
core   +1 more source

Lung function trajectory in progressive fibrosing interstitial lung disease

European Respiratory Journal, 2021
Background Proposed criteria for progressive fibrosing interstitial lung disease (PF-ILD) have been linked to increased mortality risk, but lung function trajectory after satisfying individual criteria remains unknown. Because survival is rarely employed
J. Oldham, Cathryn T. Lee, Zhe Wu, W. S. Bowman, J. V. Pugashetti, Nam Dao, J. Tonkin, Hasan Seede, G. Echt, A. Adegunsoye, F. Chua, T. Maher, C. Garcia, M. Strek, C. Newton, P. Molyneaux   +15 more
semanticscholar   +1 more source

Airway involvement in interstitial lung disease [PDF]

, 2006
PURPOSE OF REVIEW: After briefly discussing several ways to approach airway involvement in interstitial lung diseases - by diagnostic methodologies used to assess it, considering different topographical involvement, related to its presence in the diffuse
Robalo-Cordeiro, C
core   +1 more source

Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open Label Extension of a Phase 3 Randomized Controlled Trial.

American Journal of Respiratory and Critical Care Medicine, 2021
RATIONALE Tocilizumab, an anti-interleukin-6 receptor antibody, had no statistically significant effect on skin sclerosis but preserved lung function over 48 weeks in patients with early systemic sclerosis-associated interstitial lung disease in a phase ...
D. Khanna, Celia J. F. Lin, D. Furst, Bridget Wagner, M. Zucchetto, G. Raghu, F. Martinez, J. Goldin, J. Siegel, C. Denton   +9 more
semanticscholar   +1 more source